Transcode Therapeutics RNAZ
NASDAQ RNAZ
$2.97 -0.24 (-7.48%)
At close: Aug 20, 2026 · 4:00 PM EDT

Transcode Therapeutics (RNAZ) Other financing activities (2022)

Transcode Therapeutics' (RNAZ) quarterly Other financing activities came in at $5989.0 in Q1 2022.

Transcode Therapeutics (RNAZ) Other financing activities (2022) Analysis & Trends

Transcode Therapeutics (RNAZ) has 1 years of Other financing activities data on file, last reported at $5989.0 in Q1 2022.

  • Quarterly Other financing activities changed N/A year-over-year to $5989.0 in Q1 2022, while the trailing twelve-month figure through Dec 2022 was $5989.0 (changed N/A YoY) and the FY2022 annual result came in at $5989.0, down 99.98% from the prior year.
  • Other financing activities steadied at $5989.0 in Q1 2022.
  • In the past five years, Other financing activities ranged from a high of $5989.0 in Q1 2022 to a low of $5989.0 in Q1 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 137.11 Bn 129.26 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 84.98 Bn 76.99 Bn 3.93 Bn
3 Argenx Se 64.52 Bn 59.33 Bn 1.37 Bn
4 Moderna 53.23 Bn 48.09 Bn 52.00 Mn
5 BeOne Medicines 41.23 Bn 36.14 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 30.65 Bn 27.34 Bn 992.69 Mn
7 Insmed 27.15 Bn 25.99 Bn 358.27 Mn
8 Royalty Pharma 26.98 Bn 26.14 Bn -
9 BioNTech SE 26.78 Bn 8.39 Bn 668.28 Mn
10 Transcode Therapeutics 2.84 Mn 2.84 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2022 5,989.00
Mar 31, 2022 5,989.00